


# PRODUCT INFORMATION



## Milrinone

Item No. 13357

**CAS Registry No.:** 78415-72-2  
**Formal Name:** 1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile  
**Synonym:** WIN 47,203  
**MF:** C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O  
**FW:** 211.2  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 214, 270, 344 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Milrinone is supplied as a crystalline solid. A stock solution may be made by dissolving the milrinone in the solvent of choice, which should be purged with an inert gas. Milrinone is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of milrinone in these solvents is approximately 0.5 and 0.3 mg/ml, respectively.

### Description

Milrinone is an inhibitor of type 3 phosphodiesterases (PDEs), inhibiting recombinant PDE3A and PDE3B with IC<sub>50</sub> values of 0.45 and 1 μM, respectively.<sup>1</sup> It is selective for PDE3 over PDE1, PDE2, PDE4, PDE5, and PDE7 (IC<sub>50</sub>s = 263, >300, 17.5, 49.1, and 58.3 μM, respectively).<sup>1</sup> Milrinone (0.1-1 mg/kg) has positive inotropic effects, increasing cardiac contractile force in anesthetized dogs with a concomitant increase in heart rate but not blood pressure.<sup>2</sup> It also increases contractile force in models of propranolol- and verapamil-induced heart failure in anesthetized dogs when administered at an initial dose of 30 μg/kg followed by a continuous 3 μg/kg per minute infusion. Milrinone has vasodilatory effects as well, decreasing mean aortic pressure and increasing venous compliance in anesthetized dogs when administered at an initial dose of 10 μg/kg followed by a continuous 1.7-2.4 μg/kg per minute infusion.<sup>3</sup> Formulations containing milrinone have been used in the treatment of heart failure.

### References

1. Sudo, T., Tachibana, K., Toga, K., *et al.* Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. *Biochem. Pharmacol.* **59(4)**, 347-356 (2000).
2. Alousi, A.A., Canter, J.M., Montenaro, M.J., *et al.* Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. *J. Cardiovasc. Pharmacol.* **5(5)**, 792-803 (1983).
3. Lee, R.W., Gay, R.G., Lancaster, L.D., *et al.* Dog model to study the effects of pharmacologic agents on the peripheral circulation: Effects of milrinone. *J. Pharmacol. Exp. Ther.* **240(3)**, 1014-1019 (1987).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM